EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations

Yi Li, Yang He, Jian Lin, Tong Wang, Wei Wang, Zhencun Tang

Frontiers in Bioscience-Landmark · 2026-06-01 · 31 (6)

DOI: 10.31083/fbl48694 ↗

At a glance

Journal article in Frontiers in Bioscience-Landmark, published online on 2026-06-01. Written by Yi Li and 5 co-authors. Institution: 920th Hospital of Joint Logistics Support Force, PLA, 650032 Kunming, Yunnan, China. Major MEDLINE topics: Tumor Suppressor Protein p53, TOR Serine-Threonine Kinases, Vascular Malformations, Receptor, TIE-2. 36 references. The full text is freely available (open access, CC BY 4.0). Funded by: Yunnan Provincial Science and Technology Talent and Platform Planning Project, Xingdian Talents Program Famous Medical Specialty Project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Sporadic venous malformations are a prevalent vascular anomaly in the oral and maxillofacial region. Current therapeutic strategies are associated with high recurrence rates and limited applicability in critical anatomical regions. Therefore, there is a pressing demand for more effective treatment modalities to address these challenges.

Methods

This study utilized transcriptome sequencing to analyze samples from venous malformation patients and combined lesion tissue analysis, cell culture, and xenograft mouse models to investigate the pathogenic mechanisms and potential therapeutic approaches for venous malformations.

Results

Our findings indicated that the primary pathological features of venous malformations include abnormal angiogenesis and excessive activation of the phosphoinositide 3-kinase (PI3K) signaling pathway. In endothelial cells with the most common pathogenic mutation, TIE2-L914F, this mutation activates the PI3K pathway, promoting cell proliferation, inhibiting normal angiogenesis, and suppressing apoptosis. Treatment with PI3K inhibitors effectively reversed these pathological changes. More importantly, the combination of rapamycin and alpelisib exhibited superior therapeutic efficacy, not only significantly inhibiting the PI3K pathway but also activating P53 expression, thereby effectively preventing disease progression. Further validation through in vitro 3D angiogenesis assays and xenograft mouse models confirmed the therapeutic potential of this combination. The results demonstrated a marked reduction in vessel sprouting in the 3D model and inhibited both lesion size and angiogenesis in the xenograft mouse model.

Conclusions

This study is the first to demonstrate that the combination of rapamycin and alpelisib, through multi-target synergy, effectively inhibits the PI3K pathway and activates P53 expression, offering new insights and therapeutic options for the treatment of venous malformations.

Subjects

MeSH terms (MEDLINE)

Tumor Suppressor Protein p53TOR Serine-Threonine KinasesVascular MalformationsReceptor, TIE-2SirolimusProto-Oncogene Proteins c-aktAnimalsHumansMiceSignal TransductionDisease Models, AnimalMutationPhosphatidylinositol 3-KinasesFemaleCell Proliferation

Author keywords

TIE2 proteinphosphatidylinositol 3-kinasestarget of Rapamycin proteinvenous malformation

Substances

Tumor Suppressor Protein p53TOR Serine-Threonine KinasesReceptor, TIE-2SirolimusProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTEK protein, humanMTOR protein, human

Authors and institutions

  • 920th Hospital of Joint Logistics Support Force, PLA, 650032 Kunming, Yunnan, China.
  • Yunnan Key Laboratory of Stomatology, Kunming Medical University, 650500 Kunming, Yunnan, China.
  • Department of Oral and Maxillofacial Surgery, The First People's Hospital of Yunnan Province, 650032 Kunming, Yunnan, China.
  • Shiyan Key Laboratory of Comprehensive Prevention and Treatment of Oral Cancer, Department of Stomatology, Taihe Hospital, Hubei University of Medicine, 442000 Shiyan, Hubei, China.
  • Institute of Oral Diseases, School of Dentistry, Hubei University of Medicine, 442000 Shiyan, Hubei, China.

Funding

  • Yunnan Provincial Science and Technology Talent and Platform Planning Project
  • Xingdian Talents Program Famous Medical Specialty Project

Cite

APA

Li, Y., He, Y., Lin, J., Wang, T., Wang, W., & Tang, Z. (2026). AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations. Frontiers in Bioscience-Landmark, 31(6). https://doi.org/10.31083/fbl48694

Vancouver

Li Y, He Y, Lin J, Wang T, Wang W, Tang Z. AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations. Frontiers in Bioscience-Landmark. 2026;31(6). doi:10.31083/fbl48694

BibTeX
@article{Li2026,
  author = {Li, Yi and He, Yang and Lin, Jian and Wang, Tong and Wang, Wei and Tang, Zhencun},
  title = {AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {6},
  doi = {10.31083/fbl48694}
}
Start for free →